The Company expects a loss in Adjusted EBITDA in the range of $4.0 million to $6.0 million for full year 2026, as compared to a loss of $3.9 million in the full-year 2025
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical to highlight new product innovations, present data at ACFAS
- Treace Medical Issues Preliminary Q4 Results, Highlights Growth
- Treace Medical sees Q4 revenue $62.1M-$62.5M, consensus $61.76M
- Treace Medical anticipates ‘continued positive procedure volume growth’
- Treace Medical reports completion of first Lapiplasty Lightning technology case